Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: Clinical potential of neonatal Nav1.5 in breast cancer

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 206-219

  Onkal, Rustem ^a   Djamgoz, Mustafa B A ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CYPRUS INTERNATIONAL UNIVERSITY   (Turkey)

Author keywords

Alternative splicing; Antibody; Breast cancer; Cardiac; Development; Metastasis; Nav1.5; Neonatal; Neurotoxin; Oncofoetal; Pharmacology; SCN5A; siRNA; Voltage gated sodium channel

Indexed keywords

ACONITINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; BEVACIZUMAB; BOTULINUM TOXIN A; CARBAMAZEPINE; CETUXIMAB; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LIDOCAINE; LOCAL ANESTHETIC AGENT; MONOCLONAL ANTIBODY; NEUROTOXIN; PHENYTOIN; POLYCLONAL ANTIBODY; RITUXIMAB; SCORPION VENOM; SMALL INTERFERING RNA; SNAKE VENOM; SODIUM CHANNEL; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.7; TETRODOTOXIN; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; VERATRIDINE; VOLTAGE GATED SODIUM CHANNEL;

ANTINEOPLASTIC ACTIVITY; BLADDER NECK STENOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CELL MOTILITY; DRUG PENETRATION; DRUG TARGETING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; RNA SPLICING; SODIUM CURRENT; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; SODIUM CHANNELS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 71749110120     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.040     Document Type: Review

References (180)

1. Abdul M., and Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res. 21 (2001) 2045-2048
2. Abdul M., and Hoosein N. Voltage-gated sodium ion channels in prostate cancer: expression and activity. Anticancer Res. 22 (2002) 1727-1730
3. Abdul M., and Hoosein N. Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett. 186 (2002) 99-105
4. Adachi K., Toyota M., Sasaki Y., Yamashita T., Ishida S., Ohe-Toyota M., Maruyama R., Hinoda Y., Saito T., Imai K., Kudo R., and Tokino T. Identification of SCN3B as a novel p53-inducible proapoptotic gene. Oncogene 23 (2004) 7791-7798
5. Ademuyiwa F.O., and Miller K.D. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. Clin. Breast Cancer 8 (2008) S151-S156
6. Allen D.H., Lepple-Wienhues A., and Cahalan M.D. Ion channel phenotype of melanoma cell lines. J. Membr. Biol. 155 (1997) 27-34
7. Ansiaux R., and Gallez B. Use of botulinum toxins in cancer therapy. Expert Opin. Investig. Drugs 16 (2007) 209-218
8. Arcangeli A., Crociani O., Lastraioli E., Masi A., Pillozzi S., and Becchetti A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr. Med. Chem. 16 (2009) 66-93
9. Ariel I., Ayesh S., Perlman E.J., Pizov G., Tanos V., Schneider T., Erdmann V.A., Podeh D., Komitowski D., Quasem A.S., de Groot N., and Hochberg A. The product of the imprinted H19 gene is an oncofetal RNA. Mol. Pathol. 50 (1997) 34-44
10. Ashcroft F.M. From molecule to malady. Nature 440 (2006) 440-447
11. Bacac M., and Stamenkovic I. Metastatic cancer cell. Annu. Rev. Pathol. 3 (2007) 221-247
12. Bedard P.L., and Piccart-Gebhart M.J. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin. Breast Cancer 8 (2008) S157-S165
13. Behlke M.A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18 (2008) 305-319
14. Belardinelli L., Shryock J.C., and Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 4 (2006) 6-14
15. Belcher S.M., Zerillo C.A., Levenson R., Ritchie J.M., and Howe J.R. Cloning of a sodium-channel alpha-subunit from rabbit schwann-cells. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11,034-11,038
16. Bennay M., Langer J., Meier S.D., Kafitz K.W., and Rose C.R. Sodium signals in cerebellar Purkinje neurons and Bergmann glial cells evoked by glutamatergic synaptic transmission. Glia 56 (2008) 1138-1149
17. + channels confer invasive properties on human prostate cancer cells. Pflugers Arch. 447 (2004) 908-914
18. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., and Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40 (2008) 499-507
19. Berger J.C., Vander-Griend D., Stadler W.M., and Rinker-Schaeffer C. Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells. Anticancer Drugs 15 (2004) 559-568
20. Blandino J.K., Viglione M.P., Bradley W.A., Oie H.K., and Kim Y.I. Voltage-dependent sodium channels in human small-cell lung cancer cells: role in action potentials and inhibition by Lambert-Eaton syndrome IgG. J. Membr. Biol. 143 (1995) 153-163
21. + channel expression in Mat-LyLu rat prostate cancer cell line. J. Physiol. 573 (2006) 343-356
22. Brackenbury W.J., Chioni A.M., Diss J.K.J., and Djamgoz M.B. The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells. Breast Cancer Res. Treat. 101 (2007) 149-160
23. + channel activity and Transwell migration in Mat-LyLu rat prostate cancer cell line. J. Cell. Physiol. 210 (2007) 602-608
24. Brackenbury W.J., Djamgoz M.B., and Isom L.L. An emerging role for voltage-gated Na+ channels in cellular migration: regulation of central nervous system development and potentiation of invasive cancers. Neuroscientist 14 (2008) 571-583
25. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1 (2001) 118-129
26. Castillo C., Thornhill W.B., Zhu J., and Recio-Pinto E. The permeation and activation properties of brain sodium channels change during development. Brain Res. Dev. Brain Res. 144 (2003) 99-106
27. Catterall W.A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26 (2000) 13-25
28. Catterall W.A., Striessnig J., Snutch T.P., and Perez-Reyes E. International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. Pharmacol. Rev. 55 (2003) 579-581
29. Catterall W.A., Cestèle S., Yarov-Yarovoy V., Yu F.H., Konoki K., and Scheuer T. Voltage-gated ion channels and gating modifier toxins. Toxicon 49 (2007) 124-141
30. Cestele S., and Catterall W.A. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 82 (2000) 883-892
31. + channel 'neonatal' isoform. J. Neurosci. Methods 147 (2005) 88-98
32. + channel beta1 subunit. Int. J. Biochem. Cell Biol. 41 (2009) 1216-1227
33. Chuang Y.C., and Chancellor M.B. The application of botulinum toxin in the prostate. J. Urol. 176 (2006) 2375-2382
34. Clare J.J., Tate S.N., Nobbs M., and Romanos M.A. Voltage-gated sodium channels as therapeutic targets. Drug Discov. Today 5 (2000) 506-520
35. Clarkson C.W., Matsubara T., and Hondeghem L.M. Evidence for voltage-dependent block of cardiac sodium channels by tetrodotoxin. J. Mol. Cell Cardiol. 20 (1988) 1119-1131
36. Conti F., Gheri A., Pusch M., and Moran O. Use dependence of tetrodotoxin block of sodium channels: a revival of the trapped-ion mechanism. Biophys. J. 71 (1996) 1295-1312
37. Conti M. Targeting ion channels for new strategies in cancer diagnosis and therapy. Curr. Clin. Pharmacol. 2 (2007) 135-144
38. Copley R.R. Evolutionary convergence of alternative splicing in ion channels. Trends Genet. 20 (2004) 171-176
39. Cusdin F.S., Clare J.J., and Jackson A.P. Trafficking and cellular distribution of voltage-gated sodium channels. Traffic 9 (2008) 17-26
40. + channels increases during development. Jpn. Heart J. 39 (1998) 199-210
41. Diaz D., Delgadillo D.M., Hernández-Gallegos E., Ramírez-Domínguez M.E., Hinojosa L.M., Ortiz C.S., Berumen J., Camacho J., and Gomora J.C. Functional expression of voltage-gated sodium channels in primary cultures of human cervical cancer. J. Cell. Physiol. 210 (2007) 469-478
42. + current in the Mat-LyLu cell line of rat prostate cancer. Int. J. Biochem. Cell Biol. 36 (2004) 1249-1260
43. + channel activity. J. Cell. Physiol. 215 (2008) 77-81
44. + channels: Functional consequences of multiple subtypes and isoforms for physiology and pathophysiology. Eur. Biophys. J. 33 (2004) 180-193
45. Diss J.K.J., Stewart D., Pani F., Foster C.S., Walker M.M., Patel A., and Djamgoz M.B. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis. 8 (2005) 266-273
46. Diss J.K.J., Fraser S.P., Walker M.M., Patel A., Latchman D.S., and Djamgoz M.B. Beta-subunits of voltage-gated sodium channels in human prostate cancer: quantitative in vitro and in vivo analyses of mRNA expression. Prostate Cancer Prostatic Dis. 11 (2007) 325-333
47. + channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate 48 (2001) 165-178
48. Djamgoz M.B.A., and Isbilen B. Dietary compounds as anti-cancer agents: a preliminary evaluation of ion channels and membrane excitability as possible target mechanisms. Turk. J. Biochem. 31 (2006) 57-68
49. + channel activity. J. Cell. Sci. 114 (2001) 2697-2705
50. Drizin I., Gregg R.J., Scanio M.J., Shi L., Gross M.F., Atkinson R.N., Thomas J.B., Johnson M.S., Carroll W.A., Marron B.E., Chapman M.L., Liu D., Krambis M.J., Shieh C.C., Zhang X., Hernandez G., Gauvin D.M., Mikusa J.P., Zhu C.Z., Joshi S., Honore P., Marsh K.C., Roeloffs R., Werness S., Krafte D.S., Jarvis M.F., Faltynek C.R., and Kort M.E. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg. Med. Chem. 16 (2008) 6379-6386
51. Dykxhoorn D.M., and Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. 56 (2005) 401-423
52. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., Schrag D., Jamison P.M., Jemal A., Wu X.C., Friedman C., Harlan L., Warren J., Anderson R.N., and Pickle L.W. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 97 (2005) 1407-1427
53. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
54. England S. Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin. Investig. Drugs 17 (2008) 1849-1864
55. Fidler I.J. Critical determinants of metastasis. Semin. Cancer Biol. 12 (2002) 89-96
56. Fidler I.J. The organ microenvironment and cancer metastasis. Differentiation 70 (2002) 498-505
57. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3 (2003) 453-458
58. Fiske J.L., Fomin V.P., Brown M.L., Duncan R.L., and Sikes R.A. Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev. 25 (2006) 493-500
59. Fraser S.P., Ding Y., Liu A., Foster C.S., and Djamgoz M.B. Tetrodotoxin suppresses morphological enhancement of the metastatic Mat-LyLu rat prostate cancer cell line. Cell Tissue Res. 295 (1999) 505-512
60. + channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. J. Cell. Physiol. 195 (2003) 479-487
61. + channel activity. FEBS Lett. 569 (2004) 191-194
62. Fraser S.P., Diss J.K.J., Chioni A.M., Mycielska M.E., Pan H., Yamaci R.F., Pani F., Siwy Z., Krakowska M., Grzywna Z., Brackenbury W.J., Theodorou D., Koyutu{double acute}rk M., Kaya H., Battaloǧlu E., Tamburo De Bella M., Slade M.J., Tolhurst R., Palmieri C., Jiang J., Latchman D.S., Coombes R.C., and Djamgoz M.B. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin. Cancer Res. 11 (2005) 5381-5389
63. + channels in human breast cancer cells. Eur. Biophys. J. 36 (2007) S228
64. Fraser S.P., and Pardo L.A. Ion channels: functional expression and therapeutic potential in cancer. Colloquium on ion channels and cancer. EMBO Rep. 9 (2008) 512-515
65. Fulgenzi G., Graciotti L., Faronato M., Soldovieri M.V., Miceli F., Amoroso S., Annunziato L., Procopio A., and Taglialatela M. Human neoplastic mesothelial cells express voltage-gated sodium channels involved in cell motility. Int. J. Biochem. Cell Biol. 38 (2006) 1146-1159
66. Galper J.B., and Catterall W.A. Developmental changes in the sensitivity of embryonic heart cells to tetrodotoxin and D600. Dev. Biol. 65 (1978) 216-627
67. Gao R., Wang J., Shen Y., Lei M., and Wang Z. Functional expression of voltage-gated sodium channels Nav1.5 in human breast caner cell line MDA-MB-231. J. Huazhong Univ. Sci. Technol. Med. Sci. 29 (2009) 64-67
68. Gellens M.E., George Jr. A.L., Chen L.Q., Chahine M., Horn R., Barchi R.L., and Kallen R.G. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 554-558
69. Gillet L., Roger S., Besson P., Lecaille F., Gore J., Bougnoux P., Lalmanach G., and Le Guennec J.Y. Voltage-gated sodium channel activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells. J. Biol. Chem. 284 (2009) 8680-8691
70. Goldin A.L. Resurgence of sodium channel research. Annu. Rev. Physiol. 63 (2001) 871-894
71. Gomez-Varela D., Zwick-Wallasch E., Knötgen H., Sánchez A., Hettmann T., Ossipov D., Weseloh R., Contreras-Jurado C., Rothe M., Stühmer W., and Pardo L.A. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res. 67 (2007) 7343-7349
72. + currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett. 369 (1995) 290-294
73. + current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer. J. Cell. Physiol. 175 (1998) 50-58
74. Gurel B., Iwata T., Koh C.M., Yegnasubramanian S., Nelson W.G., and De Marzo A.M. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv. Anat. Pathol. 15 (2008) 319-331
75. Gustafson T.A., Clevinger E.C., Oneill T.J., Yarowsky P.J., and Krueger B.K. Mutually exclusive exon splicing of type-III brain sodium channel-alpha subunit RNA generates developmentally-regulated isoforms in rat-brain. J. Biol. Chem. 268 (1993) 18,648-18,653
76. Hagel C., and Stavrou D. Neuronal markers in non-neuronal tissues. Prog. Exp. Tumor Res. 39 (2007) 64-77
77. Hammarström A.K., and Gage P.W. Hypoxia and persistent sodium current. Eur. Biophys. J. 31 (2002) 323-330
78. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
79. + channels. J. Mol. Cell. Cardiol. 36 (2004) 185-193
80. Hille B. Ionic Channels of Excitable Membranes (1992), Sinauer Associates Inc., Sunderland (MA)
81. Hoang B.X., Graeme Shaw D., Pham P., and Levine S.A. Neuro-bioenergetic concepts in cancer prevention and treatment. Med. Hypotheses 68 (2007) 832-843
82. Hoang B.X., Levine S.A., Pham P., and Shaw D.G. Hypothesis of the cause and development of neoplasms. Eur. J. Cancer Prev. 16 (2007) 55-61
83. Hoffman E.P. Voltage-gated ion channelopathies: inherited disorders caused by abnormal sodium, chloride, and calcium regulation in skeletal muscle. Annu. Rev. Med. 46 (1995) 431-441
84. Huang C., Li M., Chen C., and Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin. Ther. Targets 12 (2008) 637-645
85. Hunter K.W. Host genetics and tumour metastasis. Br. J. Cancer 90 (2004) 752-755
86. Hunter K.W., Crawford N.P., and Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 10 1 (2008) S2
87. Isbilen B., Fraser S.P., and Djamgoz M.B. Docosahexaenoic acid (omega-3) blocks voltage-gated sodium channel activity and migration of MDA-MB-231 human breast cancer cells. Int. J. Biochem. Cell Biol. 38 (2006) 2173-2182
88. Isom L.L. Sodium channel β subunits: anything but auxiliary. Neuroscientist 7 (2001) 42-54
89. Isom L.L. The role of sodium channels in cell adhesion. Front. Biosci. 7 (2002) 12-23
90. Jarvis M.F., Honore P., Shieh C.C., Chapman M., Joshi S., Zhang X.F., Kort M., Carroll W., Marron B., Atkinson R., Thomas J., Liu D., Krambis M., Liu Y., McGaraughty S., Chu K., Roeloffs R., Zhong C., Mikusa J.P., Hernandez G., Gauvin D., Wade C., Zhu C., Pai M., Scanio M., Shi L., Drizin I., Gregg R., Matulenko M., Hakeem A., Gross M., Johnson M., Marsh K., Wagoner P.K., Sullivan J.P., Faltynek C.R., and Krafte D.S. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8520-8525
91. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. C.A. Cancer J Clin 58 (2008) 71-96
92. Kaczmarek L.K. Non-conducting functions of voltage-gated ion channels. Nat. Rev. Neurosci. 7 (2006) 761-771
93. Kim Y.I., and Neher E. IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science 239 (1988) 405-408
94. Klugbauer N., Lacinova L., Flockerzi V., and Hofmann F. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium-channel family from human neuroendocrine cells. EMBO J. 14 (1995) 1084-1090
95. Kort M.E., Drizin I., Gregg R.J., Scanio M.J., Shi L., Gross M.F., Atkinson R.N., Johnson M.S., Pacofsky G.J., Thomas J.B., Carroll W.A., Krambis M.J., Liu D., Shieh C.C., Zhang X., Hernandez G., Mikusa J.P., Zhong C., Joshi S., Honore P., Roeloffs R., Marsh K.C., Murray B.P., Liu J., Werness S., Faltynek C.R., Krafte D.S., Jarvis M.F., Chapman M.L., and Marron B.E. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem. 51 (2008) 407-416
96. Kostrzewa R.M., and Segura-Aguilar J. Botulinum neurotoxin: evolution from poison, to research tool-onto medicinal therapeutic and future pharmaceutical panacea. Neurotox. Res. 12 (2007) 275-290
97. + channel activity in rat prostate cancer cells: fractal analyses. Eur. Biophys. J. 33 (2004) 535-542
98. + channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am. J. Pathol. 150 (1997) 1213-1221
99. Le Guennec J.Y., Ouadid-Ahidouch H., Soriani O., Besson P., Ahidouch A., and Vandier C. Voltage-gated ion channels, new targets in anti-cancer research. Recent. Pat. Anticancer Drug Discov. 2 (2007) 189-202
100. Leippold T., Reitz A., and Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur. Urol. 44 (2003) 165-174
101. Leipold E., Hansel A., Borges A., and Heinemann S.H. Subtype specificity of scorpion beta-toxin Tz1 interaction with voltage-gated sodium channels is determined by the pore loop of domain 3. Mol. Pharmacol. 70 (2006) 340-347
102. Leung S.W., Teoh H., Keung W., and Man R.Y. Non-genomic vascular actions of female sex hormones: physiological implications and signalling pathways. Clin. Exp. Pharmacol. Physiol. 34 (2007) 822-826
103. 2+ currents and mimics cerebellar ataxia in vivo. Proc. Natl. Acad. Sci. U. S. A. 105 (2007) 2705-2710
104. Liotta L.A., and Clair T. Cancer. Checkpoint for invasion. Nature 405 (2000) 287-288
105. + current in rat mesenteric artery smooth muscle cells. Life Sci. 71 (2002) 1465-1473
106. Maertens C., Cuypers E., Amininasab M., Jalali A., Vatanpour H., and Tytgat J. Potent modulation of the voltage-gated sodium channel Nav1.7 by OD1, a toxin from the scorpion Odonthobuthus doriae. Mol. Pharmacol. 70 (2006) 405-414
107. Marbán E. Cardiac channelopathies. Nature 415 (2002) 213-218
108. Martin S.E., and Caplen N.J. Applications of RNA interference in mammalian systems. Annu. Rev. Genomics Hum. Genet. 8 (2007) 81-108
109. Masiero M., Nardo G., Indraccolo S., and Favaro E. RNA interference: implications for cancer treatment. Mol. Aspects Med. 28 (2007) 143-166
110. + channels are expressed presynaptically in rat dorsal root ganglia neurons. Neuroscience 159 (2009) 559-569
111. Meiri H., Sammar M., and Schwartz A. Production and use of synthetic peptide antibodies to map region associated with sodium channel inactivation. Methods Enzymol. 178 (1989) 714-739
112. Meisler M.H., Kearney J.A., Sprunger L.K., MacDonald B.T., Buchner D.A., and Escayg A. Mutations of voltage-gated sodium channels in movement disorders and epilepsy. Novartis Found. Symp. 241 (2002) 72-86
113. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today 39 (2003) 1-16
114. Monk M., and Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 20 (2001) 8085-8091
115. Morton M.E., Caffrey J.M., Brown A.M., and Froehner S.C. Monoclonal antibody to the alpha 1-subunit of the dihydropyridine-binding complex inhibits calcium currents in BC3H1 myocytes. J. Biol. Chem. 263 (1988) 613-616
116. + channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: II. Secretory membrane activity. J. Cell. Physiol. 195 (2003) 461-469
117. Mycielska M.E., and Djamgoz M.B. Cellular mechanisms of direct-current electric field effects: galvanotaxis and metastatic disease. J. Cell Sci. 117 (2004) 1631-1639
118. + channel activity. J. Physiol. 563 (2005) 393-408
119. Nakajima T., Kubota N., Tsutsumi T., Oguri A., Imuta H., Jo T., Oonuma H., Soma M., Meguro K., Takano H., Nagase T., and Nagata T. Eicosapentaenoic acid inhibits voltage-gated sodium channels and invasiveness in prostate cancer cells. Br. J. Pharmacol. 56 (2009) 420-431
120. Newsome B.W., and Ernstoff M.S. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. Br. J. Clin. Pharmacol. 66 (2008) 6-19
121. Nguyen D.X., and Massagué J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8 (2007) 341-352
122. Nikolaeva M.A., Mukherjee B., and Stys P.K. Na+-dependent sources of intra-axonal Ca2+ release in rat optic nerve during in vitro chemical ischemia. J. Neurosci. 25 (2005) 9960-9967
123. +-channel subtypes in human prostate cancer. J. Pharmacol. Sci. 109 (2009) 148-151
124. + channel expression in vitro. J. Membr. Biol. 204 (2005) 67-75
125. Onganer P.U., Seckl M.J., and Djamgoz M.B. Neuronal characteristics of small-cell lung cancer. Br. J. Cancer 93 (2005) 1197-1201
126. Onganer P.U., and Djamgoz M.B. Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel. Mol. Cancer 6 (2007) 76-86
127. Onkal R., Mattis J.H., Fraser S.P., Diss J.K., Shao D., Okuse K., and Djamgoz M.B. Alternative splicing of Nav1.5: an electrophysiological comparison of 'neonatal' and 'adult' isoforms and critical involvement of a lysine residue. J. Cell. Physiol. 216 (2008) 716-726
128. O'Rourke B., and Maack C. The role of Na dysregulation in cardiac disease and how it impacts electrophysiology. Drug Discov. Today Dis. Models 4 (2007) 207-217
129. + channels in human neuroblastoma cells are encoded by new variants of Nav1.5/SCN5A. Eur. J. NeuroSci. 22 (2005) 793-801
130. Ouwerkerk R., Jacobs M.A., Macura K.J., Wolff A.C., Stearns V., Mezban S.D., Khouri N.F., Bluemke D.A., and Bottomley P.A. Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive (23)Na MRI. Breast Cancer Res. Treat. 106 (2007) 151-160
131. Palmer C.P., Mycielska M.E., Burcu H., Osman K., Collins T., Beckerman R., Perrett R., Johnson H., Aydar E., and Djamgoz M.B. Single cell adhesion measuring apparatus (SCAMA): application to cancer cell lines of different metastatic potential and voltage-gated Na+ channel expression. Eur. Biophys. J. 37 (2008) 359-368
132. Pardo L.A., and Stühmer W. Eag1 as a cancer target. Expert Opin. Ther. Targets 12 (2008) 837-843
133. Plummer N.W., Galt J., Jones J.M., Burgess D.L., Sprunger L.K., Kohrman D.C., and Meisler M.H. Exon organization, coding sequence, physical mapping, and polymorphic intragenic markers for the human neuronal sodium channel gene SCN8A. Genomics 54 (1998) 287-296
134. Plummer N.W., and Meisler M.H. Evolution and diversity of mammalian sodium channel genes. Genomics 57 (1999) 323-331
135. Prevarskaya N., Skryma R., Bidaux G., Flourakis M., and Shuba Y. Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ. 14 (2007) 1295-1304
136. Priest B.T., Blumenthal K.M., Smith J.J., Warren V.A., and Smith M.M. ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels. Toxicon 49 (2007) 194-201
137. Prossnitz E.R., Arterburn J.B., Smith H.O., Oprea T.I., Sklar L.A., and Hathaway H.J. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu. Rev. Physiol. 70 (2008) 165-190
138. Ragsdale D.S., McPhee J.C., Scheuer T., and Catterall W.A. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9270-9275
139. Ramírez M.L., Nelson E.C., and Evans C.P. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis. 11 (2008) 216-229
140. Raymond C.K., Castle J., Garrett-Engele P., Armour C.D., Kan Z., Tsinoremas N., and Johnson J.M. Expression of alternatively spliced sodium channel alpha-subunit genes: unique splicing patterns are observed in dorsal root ganglia. J. Biol. Chem. 279 (2004) 46,234-46,241
141. Ribeiro M.A., and Costa P.F. The sensitivity of sodium channels in immature and mature rat CA1 neurones to the local anaesthetics procaine and lidocaine. Brain Res. Dev. Brain Res. 146 (2003) 59-70
142. Roberts R., and Brugada R. Genetics and arrhythmias. Annu. Rev. Med. 54 (2003) 257-267
143. Roger S., Besson P., and Le Guennec J.Y. Involvement of a novel fast inward sodium current in the invasion capacity of a breast cancer cell line. Biochim. Biophys. Acta 1616 (2003) 107-111
144. Roger S., Potier M., Vandier C., Besson P., and Le Guennec J.Y. Voltage-gated sodium channels: new targets in cancer therapy?. Curr. Pharm. Des. 12 (2006) 3681-3695
145. Roger S., Rollin J., Barascu A., Besson P., Raynal P.I., Iochmann S., Lei M., Bougnoux P., Gruel Y., and Le Guennec J.Y. Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines. Int. J. Biochem. Cell Biol. 39 (2007) 774-786
146. Rosker C., Lohberger B., Hofer D., Steinecker B., Quasthoff S., and Schreibmayer W. The TTX metabolite 4, 9-anhydro-TTX is a highly specific blocker of the Nav1.6 voltage-dependent sodium channel. Am. J. Physiol. Cell. Physiol. 293 (2007) 783-789
147. Ruan Y., Liu N., and Priori S.G. Sodium channel mutations and arrhythmias. Nat. Rev. Cardiol. 6 (2009) 337-348
148. + current during cardiac ischemia and hypoxia. J. Cardiovasc. Electrophysiol. 17 (2006) S96-S103
149. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura A., Lawrence Jr. J., Berstein L., and Yue W. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 12 (2005) S61-S73
150. Santen R.J., Song R.X., Masamura S., Yue W., Fan P., Sogon T., Hayashi S., Nakachi K., and Eguchi H. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv. Exp. Med. Biol. 630 (2008) 19-34
151. Sarao R., Gupta S.K., Auld V.J., and Dunn R.J. Developmentally regulated alternative RNA splicing of rat-brain sodium-channel messenger-RNAs. Nucleic Acids Res. 19 (1991) 5673-5679
152. Schwirzke M., Schiemann S., Gnirke A.U., and Weidle U.H. New genes potentially involved in breast cancer metastasis. Anticancer Res. 19 (1999) 1801-1814
153. Shao D., Okuse K., and Djamgoz M.B.A. Protein-protein interactions involving voltage-gated sodium channels: post-translational regulation, intracellular trafficking and functional expression. Int. J. Biochem. Cell Biol. 41 (2009) 1471-1481
154. Sikes R.A., Walls A.M., Brennen W.N., Anderson J.D., Choudhury-Mukherjee I., Schenck H.A., and Brown M.L. Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clin. Prostate Cancer 2 (2003) 181-187
155. Smith P., Rhodes N.P., Shortland A.P., Fraser S.P., Djamgoz M.B., Ke Y., and Foster C.S. Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett. 423 (1998) 19-24
156. Son D.J., Park M.H., Chae S.J., Moon S.O., Lee J.W., Song H.S., Moon D.C., Kang S.S., Kwon Y.E., and Hong J.T. Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappaB. Mol. Cancer Ther. 6 (2007) 675-683
157. Soroceanu L., Gillespie Y., Khazaeli M.B., and Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 58 (1998) 4871-4879
158. Vaidya K.S., and Welch D.R. Metastasis suppressors and their roles in breast carcinoma. J. Mammary Gland Biol. Neoplasia 12 (2007) 175-190
159. Ventura A.C., and Merajver S.D. Genetic determinants of aggressive breast cancer. Annu. Rev. Med. 59 (2008) 199-212
160. Wall N.R., and Shi Y. Small RNA: can RNA interference be exploited for therapy?. Lancet 362 (2003) 1401-1403
161. + channels in the brain. J. Neurogenet. 22 (2008) 57-75
162. Wang M., Liu Q., Luo H., Li J., Tang J., Xiao Y., and Liang S. Jingzhaotoxin-II, a novel tarantula toxin preferentially targets rat cardiac sodium channel. Biochem. Pharmacol. 76 (2008) 1716-1727
163. Wang W.X., and Ji Y.H. Scorpion venom induces glioma cell apoptosis in vivo and inhibits glioma tumor growth in vitro. J. Neurooncol. 73 (2005) 1-7
164. Wang, Y., Jones, P.J., Batts, T.W., Landry, V., Patel, M.K., Brown,
165. Waxman S.G. Acquired channelopathies in nerve injury and MS. Neurology 56 (2001) 1621-1627
166. Waxman S.G. Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. Nat. Neurosci. 10 (2007) 405-409
167. Weigelt B., Hu Z., He X., Livasy C., Carey L.A., Ewend M.G., Glas A.M., Perou C.M., and Van't Veer L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65 (2005) 9155-9158
168. Welch D.R., Steeg P.S., and Rinker-Schaeffer C.W. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res. 2 (2000) 408-416
169. Welch D.R. Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res. 6 (2004) 61-64
170. Welch D.R. Do we need to redefine a cancer metastasis and staging definitions?. Breast Dis. 26 (2006) 3-12
171. Williams E.L., and Djamgoz M.B. Nitric oxide and metastatic cell behaviour. BioEssays 27 (2005) 1228-1238
172. Williams B.S., Felix J.P., Priest B.T., Brochu R.M., Dai K., Hoyt S.B., London C., Tang Y.S., Duffy J.L., Parsons W.H., Kaczorowski G.J., and Garcia M.L. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry 46 (2007) 14,693-14,703
173. + exchanger during ischemia and preconditioning in the isolated rat heart. Circ. Res. 85 (1999) 723-730
174. Xiao Y., Bingham J.P., Zhu W., Moczydlowski E., Liang S., and Cummins T.R. Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain II voltage sensor in the closed configuration. J. Biol. Chem. 283 (2008) 27,300-27,313
175. Xu Y.Q., Pickoff A.S., and Clarkson C.W. Evidence for developmental changes in sodium channel inactivation gating and sodium channel block by phenytoin in rat cardiac myocytes. Circ. Res. 69 (1991) 644-656
176. Xu Y.Q., Pickoff A.S., and Clarkson C.W. Developmental changes in the effects of lidocaine on sodium channels in rat cardiac myocytes. J. Pharmacol. Exp. Ther. 262 (1992) 670-676
177. Xu S.Z., Zeng F., Lei M., Li J., Gao B., Xiong C., Sivaprasadarao A., and Beech D.J. Generation of functional ion-channel tools by E3 targeting. Nat. Biotechnol. 23 (2005) 1289-1293
178. Zangemeister-Wittke U. Antibodies for targeted cancer therapy - technical aspects and clinical perspectives. Pathobiology 72 (2005) 279-286
179. Zecevic D., Djurisic M., Cohen L.B., Antic S., Wachowiak M., Falk C.X., and Zochowski M.R. Imaging nervous system activity with voltage-sensitive dyes. Curr. Protoc. Neurosci. (2003) Chapter 6, Unit 6.17
180. Zhou B.Y., Ma W., and Huang X.Y. Specific antibodies to the external vestibule of voltage-gated potassium channels block current. J. Gen. Physiol. 111 (1998) 555-563